Loading...
Market
Vutrisiran first RNA silencing therapy for ATTR-CM on the market by end of 2024?
5
Resolution / Starting Odds
Yes • 50%
No • 50%
Market release announcements from Alnylam and competitive analysis reports
Story
Alnylam's Vutrisiran Shows Positive Results in Phase 3 Heart Disease Study, Stock Surges 30%
Jun 24, 2024, 11:15 AM
Alnylam Pharmaceuticals announced positive topline results from its HELIOS-B Phase 3 study of vutrisiran, a treatment for transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM). The late-stage study achieved statistical significance on primary and all secondary endpoints in both overall and monotherapy populations. Vutrisiran demonstrated a reduction in the risk of death and recurrent cardiovascular complications. This success likely paves the way for vutrisiran to become the first RNA silencing therapy on the market for ATTR amyloidosis with cardiomyopathy. The positive results have also led to a significant increase in Alnylam's stock price, which surged by 30%.
View original story
Similar markets
Yes • 50%
No • 50%
Pfizer • 25%
Ionis Pharmaceuticals • 25%
Eidos Therapeutics • 25%
Other • 25%
Approval • 33%
Conditional Approval • 33%
Rejection • 34%
FDA approval • 25%
New clinical trial results • 25%
Partnership with another company • 25%
No major announcement • 25%
Less than 10% • 25%
10%-20% • 25%
20%-30% • 25%
More than 30% • 25%
Market leader • 33%
Second place • 33%
Third place or lower • 33%
Vutrisiran leads • 25%
Acoramidis leads • 25%
Both have equal market share • 25%
Neither has significant market share • 25%